Roche Says FDA's Evaluation Of This Columvi Combination For R/R Dlbcl Is Ongoing And A Decision On Approval Is Expected By 20 July 2025
RefinitivLesedauer weniger als 1 min
Roche Holding AG 
RO:
ROCHE PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING ON COLUMVI COMBINATION FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
ROCHE HOLDING AG - FDA'S EVALUATION OF THIS COLUMVI COMBINATION FOR R/R DLBCL IS ONGOING AND A DECISION ON APPROVAL IS EXPECTED BY 20 JULY 2025
Loggen Sie sich ein oder erstellen Sie ein fortwährend kostenloses Konto, um diese News lesen zu können